EVEROLIMUS vs MEKINIST

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. EVEROLIMUS and MEKINIST are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	MEKINIST
Rating	70/100	70/100
Pharmacy pays	~$229.16 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	TRAMETINIB DIMETHYL SULFOXIDE
Manufacturer	Biocon Pharma	Novartis
Dosage forms	Tablet	Powder, Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Non-Small-Cell Lung Carcinoma, Melanoma

everolimus mekinist

Rating

70/100

Pharmacy pays

~$229.16 /30

—

Type

Active ingredient

EVEROLIMUS

TRAMETINIB DIMETHYL SULFOXIDE

Manufacturer

Biocon Pharma

Novartis

Dosage forms

Tablet

Powder, Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Non-Small-Cell Lung Carcinoma, Melanoma

Frequently asked questions

Which is better-rated, Everolimus or Mekinist?

Everolimus and Mekinist are tied at 3.5 out of 5 by our independent rating.

What is the difference between Everolimus and Mekinist?

Everolimus contains Everolimus, while Mekinist contains Trametinib Dimethyl Sulfoxide — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.